Established in 2005 and listed on the Science and Technology Innovation Board of Shanghai Stock Exchange (stock code: 688393, stock abbreviation: LBP) on August 20th, 2020, Guangzhou LBP Medicine Science & Technology Co., Ltd. ("LBP" for short ) is the first listed company in the field of pathological diagnosis in China. Headquartered in Science City, LBP owns a newly-built industrial park of nearly 30, 000 m2 and is mainly engaged in the research and development, production, sales and service of in vitro diagnostic reagents and instruments.

Since its establishment, it has been focusing on the main business with intensive cultivation and has set up a diversified technology platform and developed a number of core technologies independently, such as sedimentation liquid-based cytology, reverse DOT hybridization PCR preparation, real-time fluorescence PCR preparation, FISH probe labeling, IHC pathological diagnosis antibody screening and quality control technologies and related supporting instrument manufacturing technologies. It is one of the manufacturers with the most complete product lines and the most abundant varieties in the field of pathological diagnosis in China, which can meet the needs of medical institutions at different levels. Both LBP and its subsidiary LBP Automation have obtained the national high-tech enterprise certificate, with 16 core products winning the title of "Guangdong High-tech Products", and meanwhile won many honors such as 2018 Guangdong Innovative Enterprise (Pilot) and Guangdong Pathological Diagnosis Engineering Technology Research Center. The products have passed the CE certification, BSI certification, ISO13485 certification and the quality certification of the Ministry of Health, Labour and Welfare of Japan.